Treatment of severe covid-19 with interleukin 6 receptor inhibition.
作者信息
Rajasundaram Skanda, Burgess Stephen, Gill Dipender
机构信息
University of Oxford, Oxford, UK.
University of Cambridge, Cambridge, UK.
出版信息
BMJ Med. 2022 Mar 2;1(1):e000144. doi: 10.1136/bmjmed-2022-000144. eCollection 2022.
Abstract
摘要
相似文献
1
Treatment of severe covid-19 with interleukin 6 receptor inhibition.使用白细胞介素6受体抑制剂治疗重症新冠病毒肺炎。
BMJ Med. 2022 Mar 2;1(1):e000144. doi: 10.1136/bmjmed-2022-000144. eCollection 2022.
2
PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection.在 SARS-CoV-2 感染的炎症阶段抑制 PCSK9。
J Am Coll Cardiol. 2023 Jan 24;81(3):224-234. doi: 10.1016/j.jacc.2022.10.030.
3
Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19.CAPSID 随机临床试验中恢复期血浆治疗重症 COVID-19 患者的细胞因子水平与良好临床结局相关。
Front Immunol. 2022 Oct 6;13:1008438. doi: 10.3389/fimmu.2022.1008438. eCollection 2022.
4
Role of Tocilizumab in the Treatment of COVID-19 Patients with Cytokine Storm: A Case Series.托珠单抗治疗 COVID-19 细胞因子风暴患者的作用：病例系列。
JNMA J Nepal Med Assoc. 2022 Aug 1;60(252):727-731. doi: 10.31729/jnma.7364.
5
An open label trial of anakinra to prevent respiratory failure in COVID-19.阿那白滞素预防 COVID-19 呼吸衰竭的开放标签试验。
Elife. 2021 Mar 8;10:e66125. doi: 10.7554/eLife.66125.
6
Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report.白细胞介素-1 受体拮抗剂阿那白滞素联合瑞德西韦治疗重症 COVID-19：一例报告。
Int J Infect Dis. 2020 Aug;97:215-218. doi: 10.1016/j.ijid.2020.05.050. Epub 2020 May 16.
7
The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical).炎症细胞因子（白细胞介素-1 和白细胞介素-6）在 COVID-19（轻症、重症和危重症）不同阶段作为潜在生物标志物的作用。
J Interferon Cytokine Res. 2023 Apr;43(4):147-163. doi: 10.1089/jir.2022.0185.
8
Liver Injury and Elevated Levels of Interleukins, Interleukin-2 Receptor, and Interleukin-6 Predict the Severity in Patients With COVID-19.肝脏损伤以及白细胞介素、白细胞介素-2 受体和白细胞介素-6 水平升高可预测 COVID-19 患者的严重程度。
Front Public Health. 2021 Dec 14;9:778340. doi: 10.3389/fpubh.2021.778340. eCollection 2021.
9
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.白细胞介素-1和白细胞介素-6抑制与COVID-19合并高炎症患者标准治疗的比较：一项队列研究
Lancet Rheumatol. 2021 Apr;3(4):e253-e261. doi: 10.1016/S2665-9913(21)00012-6. Epub 2021 Feb 3.
10
Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review).白细胞介素-6信号通路阻断治疗新型冠状病毒肺炎细胞因子释放综合征（综述）
Exp Ther Med. 2021 Jan;21(1):24. doi: 10.3892/etm.2020.9456. Epub 2020 Nov 9.
引用本文的文献
1
Mendelian randomization as a tool to inform drug development using human genetics.孟德尔随机化作为一种利用人类遗传学为药物研发提供信息的工具。
Camb Prism Precis Med. 2023 Feb 8;1:e16. doi: 10.1017/pcm.2023.5. eCollection 2023.
2
-a new journal from .- 来自……的一本新期刊。 （你提供的原文不完整，这是根据现有内容尽量完整翻译的结果）
BMJ Med. 2022 Mar 2;1(1):e000176. doi: 10.1136/bmjmed-2022-000176. eCollection 2022.
本文引用的文献
1
Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis.托珠单抗和萨瑞鲁单抗单独或与皮质类固醇联合用于治疗新冠肺炎：系统评价和网状荟萃分析
BMJ Med. 2022 Feb 28;1(1):e000036. doi: 10.1136/bmjmed-2021-000036. eCollection 2022.
2
Morning Cortisol and Circulating Inflammatory Cytokine Levels: A Mendelian Randomisation Study.早晨皮质醇和循环炎症细胞因子水平：一项孟德尔随机研究。
Genes (Basel). 2022 Jan 8;13(1):116. doi: 10.3390/genes13010116.
3
Leveraging genetic data to investigate the effects of interleukin-6 receptor signalling on levels of 40 circulating cytokines.利用遗传数据研究白细胞介素-6受体信号传导对40种循环细胞因子水平的影响。
Br J Clin Pharmacol. 2022 Mar;88(3):1373-1378. doi: 10.1111/bcp.15079. Epub 2021 Oct 7.
4
JAK Inhibitors - More Than Just Glucocorticoids.JAK抑制剂——不仅仅是糖皮质激素。
N Engl J Med. 2021 Jul 29;385(5):463-465. doi: 10.1056/NEJMe2108667.
5
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.COVID-19 住院患者中使用白细胞介素 6 拮抗剂与死亡率的关系：一项荟萃分析。
JAMA. 2021 Aug 10;326(6):499-518. doi: 10.1001/jama.2021.11330.
6
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
7
We need clinical guidelines fit for a pandemic.我们需要适用于大流行的临床指南。
BMJ. 2021 Apr 29;373:n1093. doi: 10.1136/bmj.n1093.
8
Interleukin-6: obstacles to targeting a complex cytokine in critical illness.白细胞介素-6：危重病中靶向一种复杂细胞因子的障碍。
Lancet Respir Med. 2021 Jun;9(6):643-654. doi: 10.1016/S2213-2600(21)00103-X. Epub 2021 Apr 16.
9
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
10
Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study.针对 COVID-19 干预措施评估的研究证据在预印本中报告的变化：元研究。
BMC Med. 2020 Dec 17;18(1):402. doi: 10.1186/s12916-020-01880-8.
Zotero 插件